Hypermarcas (OTCMKTS:HYPMY) Shares Down 6% – Here’s Why

Hypermarcas (OTCMKTS:HYPMY) was down 6% during trading on Monday . The company traded as low as $3.75 and last traded at $3.75. 2,014 shares changed hands during mid-day trading, a decline of 91% from the average session volume of 23,060 shares. The stock had previously closed at $3.99.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Jefferies Financial Group upgraded Hypermarcas to a “strong-buy” rating in a research note on Monday, July 20th. Zacks Research upgraded shares of Hypermarcas to a “hold” rating in a report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Hypermarcas has a consensus rating of “Buy”.

Hypermarcas Price Performance

The stock has a fifty day moving average of $4.13 and a 200 day moving average of $4.38. The firm has a market capitalization of $2.92 billion, a P/E ratio of 8.65 and a beta of 0.71.

Hypermarcas (OTCMKTS:HYPMY) last announced its earnings results on Wednesday, April 29th. The company reported $0.10 earnings per share (EPS) for the quarter. The firm had revenue of $383.13 million during the quarter. Hypermarcas had a return on equity of 14.08% and a net margin of 19.41%. Equities analysts forecast that Hypermarcas will post 0.53 EPS for the current fiscal year.

Hypermarcas Company Profile

Hypermarcas SA is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors.

Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products.